Study of Impact app for advanced melanoma patients on immunotherapy
Part of Cancer clinical trials.
This trial is testing whether a digital tool called Impact can help support patients with advanced melanoma who are receiving immunotherapy drugs like Nivolumab, alone or in combination. The goal is to see if the app helps manage treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage III (unresectable) or stage IV cutaneous melanoma that has spread.
- Your doctor must plan to treat you with Nivolumab alone or Nivolumab plus another immunotherapy (like Ipilimumab or Relatlimab), based on your PD-L1 levels.
- You must have tumors that can be measured on scans (CT or MRI).
- You must be in fairly good health (ECOG score 0 or 1), meaning you can do most daily activities.
- You must not have had prior treatment for advanced melanoma (except certain radiotherapy finished at least 2 weeks ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study looks at whether extra monitoring and faster referrals to specialists can help manage side effects from immunotherapy (a treatment that helps your immune system fight cancer). It may make treatment easier to handle.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Hear when a new Locally Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.